Plus you can't help but smile at what it states in their recent 8k Filing:
On September 30, 2014, Zogenix, Inc. (the “Company”) submitted a supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration for a modified formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, which has been designed to have abuse deterrent properties. The Company anticipates a target action date on the sNDA during the first quarter of 2015, and if approved, a transition from the currently marketed product to this new formulation of Zohydro ER in the second quarter of 2015.